Track investigational product from manufacture through site distribution to individual patient dosing, including cold-chain conditions where required. The sponsor holds a verified, gap-free record that supports the trial's regulatory submission.
Close every accountability gap between drug manufacture and the patient who received the dose.
01.
The Traceability Ledger anchors each investigational unit from manufacture to site to patient dose, so drug accountability has no gap that could weaken the submission.
02.
The Cold-Chain Monitoring module logs storage conditions for temperature-sensitive product, so a dose administered outside range is flagged rather than silently included.
03.
The Compliance Attestations module binds each dosing event to the protocol's arm and schedule, so a deviation is recorded rather than lost.
04.
Kit identities are tracked without revealing arm assignment on-chain, so accountability is maintained while the blind is preserved.
05.
Dispensed, returned, and destroyed units reconcile against what was shipped to each site, producing an auditable balance at any time.
06.
A sponsor or inspector pulls the full chain for any unit or patient, replacing site paper logs with a verifiable record for the submission.
Follow one investigational kit from manufacture through site receipt to a recorded patient dose.
06:12:50
[SYS] Registering investigational kit KIT_3120...
06:12:50
[CMD] manufacture { batch: "IP_88", storage: "2C_8C" }
06:12:51
[AUTH] Binding manufacturing attestation...
06:12:51
[OK] Kit KIT_3120 anchored at block 9312050.
Cerulea decomposes trial drug supply into modular contracts. Each layer manufactures, distributes, doses, and reconciles without a gap that could jeopardize the submission.
Investigational drug accountability is a horizontal capability. Here is how different actors in a clinical trial put it to work.
Hold a gap-free accountability record from manufacture to dose, so the drug accountability section of a regulatory submission rests on verified data rather than reconciled site paper.
Key Asset Types
Confirm cold-chain integrity on receipt and record each dose against the protocol under blind, replacing manual drug logs with a verifiable inventory.
Key Asset Types
Trace any unit or subject dose in one query during an inspection, confirming trial integrity from a tamper-evident chain instead of site binders.
Key Asset Types
Whether you are bridging an interactive response system or capturing dosing from site software, Cerulea routes both into one accountability record.
For sponsors on legacy IRT and supply systems. Manufacture, shipment, and dosing events are translated into signed on-chain kit records through the API gateway.
IRT / Supply System
Sponsor & CRO Platforms
Cerulea API Gateway
Event Hashing & Sealing
Cerulea Private Chain
Investigational Supply Ledger
For investigator sites on a signed client. Receipt and dosing events are recorded from site software directly to the ledger under the trial blind.
Site Client
Investigator Systems
Consortium Validators
Supply Consensus
Cerulea Ledger
Trial Accountability Record
Building an investigational supply ledger with cold-chain assurance, blinded dosing records, and on-demand reconciliation from scratch requires specialised engineers and long trial-system integration cycles. Calculate your exact deployment speed using Cerulea.
Traditional Deployment
Solidity Coding & Audits
~ 13 Months
Visual Compilation
WASM Logical Artifacts
~ 4 Weeks
The legacy timeline reflects clinical supply integration benchmarks. Wiring IRT and supply systems, building blinded dosing and cold-chain logic, and shipping reconciliation for an average trial takes a baseline of 9 months. Building the same architecture on Cerulea takes a baseline of 2 weeks, because Cerulea Studio visually translates your supply and dosing rules into pre-audited WebAssembly binaries and provisions the accountability ledger instantly.